Personalized Approaches to the Use of the Antioxidant Ethoxidol in Patients with Coronary Heart Disease

To develop a personalized approach to the use of ethoxidol in patients with CHD based on the definition of criteria for predicting the cytoprotective properties of this drug when tested in vitro. With the introduction of ethoxidol into a sample with a leukocyte suspension, a significant increase in VIcells by 21% (from 41% to 62%, p <0.001) was observed, which indicates the presence of a cytoprotective property in this drug. A more detailed analysis of the dynamics of the VIcells index showed two variants of changes in cell viability: in 80% of patients VIcells was increased, on average, by 28% (from 36% to 64%, p <0.001) and in 20% of patients VI cells was decreased, on average, by 10% (from 68% to 58%, p <0.05). A number of conditions for the initial state of a patient with CHD were identified for the manifestation of cytoprotective properties in ethoxidol: a proatherogenic cholesterol profile (with a serum cholesterol level above 6.6 mmol/l and a high-density lipoprotein level below 1.6 mmol /l), impaired antioxidant status ( low level of serum catalase activity - less than 5 μcatal/l), signs of mitochondrial dysfunction (increased serum urea levels above 8.3 mmol/l, decreased total blood protein levels below 76 g/l), depletion of the adaptation system function (a decrease in the level of lymphocytes in the blood less than 35% and an increase in the level of neutrophils more than 52%), the normal state of thrombopoiesis (the number of immature platelets is not more than 7%).